Serum levels of tumor necrosis factor-α (tnfα)and soluble tnf receptors in human immunodeficiency virus type 1 infection-correlationsto clinical, immunologic, and virologic parameters

Journal of Infectious Diseases

Volumn 169, Issue 2, 1994, Pages 420-424

  Aukrust, Pål ^a,b   Liabakk, Nina Beate ^a,b   Müller, Fredrik ^a,b   Lien, Egil ^a,b   Espevik, Terje ^a,b   Frøland, Stig S ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; BIOASSAY; BLOOD LEVEL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PROGNOSIS; SERUM; SURVIVAL; SYMPTOMATOLOGY;

ADULT; BIOPTERIN; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN; LEUKOCYTE COUNT; NEOPTERIN; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0028140219     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.2.420     Document Type: Article

References (15)

1. Matsuyama T. Kobayashi N, Yamamoto N. Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
2. Lahdevirta J Maury CPJ, Teppo AM, Repo H. Elevated levels of circulatingcachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. AmJMed 1988;85:289-91.
3. Grunfeld C, Kotler DP, Shigenaga JK, ct al. Circulating interferon a levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-60.
4. Engelmann H. Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531-6.
5. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36; 1S-14S.
6. Liabakk NB, Sundan A. Lien E. et al. The release of p55 receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods 1993;163:145-54.
7. Espevik T, Nissen Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
8. Brinchmann JE, Vartdal F Gaudernack G et al. Direct immunomag-netic quantification of lymphocyte subsets in blood. Clin Exp Immunol 1988:71:182-6.
9. Godfried MH, van der Poll T, Jansen J, et al. Soluble receptors for tumor necrosis factor, a putative marker for disease progression in HIV infection. AIDS 1993;7:33-6.
10. Petersen CM, Nykjaer A, Christiansen BS, Heickendorf L, Mogensen SC. Mßller B. Bioactive human recombinant tumor necrosis factoralpha: An unstable dimer? Eur J Immunol 1989;19:1887-94.
11. Linde A, Andersson B, Svenson SB, et al. Serum levels of iymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:994-1000.
12. Kalinkovich A, Livshits G. Engelmann H, et al. Soluble tumor necrosis factor receptors (sTNF-R) and HIV infection: Correlation to C'D8+ lymphocytes. Clin Exp Immunol 1993;93:350-5.
13. Aderka D. Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
14. Howard OMZ, Clouse KA. Smith C. Goodwin RG, Farrar WL. Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation. Proc Natl Acad Sei USA 1993;90:2335-9.
15. Lantz M, Malik S. Slevin ML. Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-6.